The availability of novel GIP therapies for weight management is rapidly evolving in the United States . Semaglutide, initially known for diabetes care , has demonstrated substantial results in supporting reduction in body fat , a trend replicated by Tirzepatide, a dual receptor activator acting on both GLP-1 and gastric inhibitory polypeptide. … Read More